

Photodynamic therapy for bile duct cancer

1 Guidance

- 1.1 Current evidence on the safety and efficacy of photodynamic therapy (PDT) for bile duct cancer does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research.
- 1.2 Clinicians wishing to undertake PDT for bile duct cancer should take the following actions.
- Inform the clinical governance leads in their Trusts.
 - Ensure that patients understand the uncertainty about the procedure's safety and efficacy and provide them with clear written information. Use of the Institute's *Information for the public* is recommended.
 - Audit and review clinical outcomes of all patients having PDT for bile duct cancer.
- 1.3 Publication of safety and efficacy outcomes will be useful. A randomised trial (PHOTOSTENT 2) is in progress and clinicians are encouraged to enter patients in this trial (www.ncrn.org.uk/portfolio/data.asp?ID=1461). The Institute may review the procedure upon publication of further evidence.

2 The procedure

2.1 Indications

- 2.1.1 Bile duct cancer may prevent bile flowing from the liver to the intestine. Early cancers are often asymptomatic, but as the disease advances patients may experience symptoms from biliary obstruction, such as jaundice, itchy skin, abdominal discomfort, loss of appetite, loss of weight and fever. PDT is a palliative treatment option for bile duct cancer.

- 2.1.2 Treatment options depend on the stage, size, position and type of tumour. Bile duct cancer is not usually diagnosed before the symptoms of biliary obstruction occur, by which time the cancer may be too advanced for curative surgical resection. Options for palliative treatment include surgical bypass of the bile duct or the insertion of a stent using surgical, endoscopic or percutaneous techniques. The benefits of other palliative treatments such as radiotherapy, chemotherapy and brachytherapy are still being investigated.

2.2 Outline of the procedure

- 2.2.1 PDT produces localised tissue necrosis. A photosensitising agent is applied that is absorbed into the tumour tissue. The area is then exposed to laser light of an appropriate wavelength.
- 2.2.2 PDT is usually administered in conjunction with a biliary stenting procedure. The photosensitising agent is injected intravenously and photoactivation is performed approximately 48 hours later. A laser is inserted through a translucent endoscopic catheter situated close to the tumour, or it is placed directly across the tumour. Radiological control is used to ensure correct positioning of the laser fibre. Patients remain in subdued lighting for about 3 days after injection to avoid skin photosensitivity and are then gradually readapted to light. The treatment can be repeated.

2.3 Efficacy

- 2.3.1 A randomised controlled study of 39 patients reported that those treated with PDT and biliary stenting had a significantly longer median survival time than patients treated with biliary stenting

Interventional Procedure Guidance 134

This guidance is written in the following context

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Interventional procedures guidance is for health professionals and people using the NHS in England, Wales and Scotland.

This guidance is endorsed by NHS QIS for implementation by NHSScotland.

alone (493 days versus 98 days, $p < 0.0001$). This study was terminated prematurely because PDT was so superior to stenting alone. Several quality-of-life scores were significantly improved after PDT, including global quality of life, fatigue, itching and weight loss. No significant improvements in quality-of-life scores were reported for the patients receiving biliary stenting alone. A non-randomised study of 44 patients reported that the mean survival after PDT and biliary stenting was 16 months, compared with 12.5 months after biliary stenting alone. For more details, refer to the Sources of evidence (see right).

- 2.3.2 The Specialist Advisors considered that there is not yet enough data to draw clear conclusions about the effect of PDT on survival. One Specialist Advisor stated that this procedure is only effective for tumours that are in visual proximity to the light source.

2.4 Safety

- 2.4.1 The most common complications were cholangitis, affecting between 15% (3/20) and 56% (13/23) of patients, and photosensitivity, which was reported in 0% (0/8) to 33% (2/6) of patients. Other reported complications included bilioma, cholecystitis, stenosis and haemobilia. For more details, refer to the Sources of evidence.
- 2.4.2 The Specialist Advisors stated that potential adverse effects of the procedure include cholangitis, photosensitivity, stenosis of the biliary tree, biliary perforation, acute pancreatitis, bleeding and pain.

2.5 Other comments

- 2.5.1 It was noted that efficacy may depend on the particular photosensitising agent used.
- 2.5.2 The initial evidence suggests that PDT may be an efficacious palliative technique in patients with bile duct cancer.

Andrew Dillon
Chief Executive
July 2005

Ordering information

Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting reference number N0891. *Information for the public* can be obtained by quoting reference number N0892.

The distribution list for this guidance is available at www.nice.org.uk/IPG134distributionlist

Published by the National Institute for Health and Clinical Excellence, July 2005; ISBN 1-84629-061-9

© National Institute for Health and Clinical Excellence, July 2005. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Information for the public

NICE has produced information describing its guidance on this procedure for patients, carers and those with a wider interest in healthcare. It explains the nature of the procedure and the decision made, and has been written with patient consent in mind. This information is available from www.nice.org.uk/IPG134publicinfo

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.

Interventional procedure overview of photodynamic therapy for bile duct cancer, October, 2004

Available from www.nice.org.uk/ip273overview